Bone Biologics Highlights 2025 Key Operational, Scientific, and Corporate Milestones and Provides 2026 Outlook

Rhea-AI Summary

Bone Biologics (NASDAQ: BBLG) summarized 2025 operational, scientific, and corporate milestones and provided a 2026 outlook. Key 2025 achievements include extending validated shelf life of its rhNELL-1 protein to 24 months, completing a registered public offering raising $5.0 million in Q2 2025, filing a U.S. patent application for its rhNELL-1 bone regeneration technology, and regaining Nasdaq minimum bid price compliance in June 2025. For 2026 the company plans to advance its NB1 clinical program with expected completion of patient enrollment in its first-in-human trial, continue manufacturing and regulatory readiness efforts, pursue additional patent protection, and maintain capital discipline.

Positive

• rhNELL-1 shelf life extended to 24 months
• Completed registered offering raising $5.0 million in Q2 2025
• Regained Nasdaq minimum bid price compliance in June 2025
• Filed U.S. patent application strengthening IP portfolio

Negative

• Clinical program early-stage with first-in-human enrollment still ongoing
• Registered offering may cause share dilution for existing shareholders

Key Figures

rhNELL-1 shelf life 24 months Validated shelf life for lead rhNELL-1 protein product candidate

Prior shelf-life milestone 18 months Earlier validated stability milestone for rhNELL-1

Earlier shelf-life milestone 12 months Initial validated stability milestone for rhNELL-1

Public offering proceeds $5 million Registered public offering completed in Q2 2025

NB1 trial first-in-human Company expects completion of patient enrollment in first-in-human trial

Current share price $1.57 Price before the 2026 outlook announcement

52-week high $7.74 High over the last 52 weeks

52-week low $1.30 Low over the last 52 weeks

Market Reality Check

$1.62 Last Close

Volume Volume 41,549 is well below the 876,750 20-day average, indicating light trading interest ahead of this update. low

Technical Shares at $1.57 are trading below the $3.06 200-day moving average and 79.72% below the 52-week high.

Peers on Argus

BBLG gained 1.29% while close peers were mixed: VERO up 2.01%, but NUWE, VTAK, NAOV, and TIVC down between roughly ~2–7%, suggesting a stock-specific reaction rather than a sector-wide move.

Historical Context

Date	Event	Sentiment	Move	Catalyst
Dec 23	Shelf-life extension	Positive	+4.3%	Extended validated rhNELL-1 product shelf life to 24 months.
Sep 04	Corporate update	Positive	+37.7%	CEO letter on NB1 trial progress, IP steps, and $5M financing.
Sep 03	Conference participation	Neutral	-2.4%	Announcement of attendance at H.C. Wainwright investment conference.

Pattern Detected

Recent fundamentally positive updates (shelf-life extension, CEO letter) were followed by positive price reactions, while a conference appearance saw a modest decline.

Recent Company History

Over the past months, Bone Biologics highlighted operational and clinical milestones tied to rhNELL-1 and NB1. On Sep 3, 2025, participation in the H.C. Wainwright conference saw a modest share decline despite increased visibility. A Sep 4, 2025 CEO letter detailing NB1’s first-in-human study, extended 18‑month shelf life, and a $5 million offering coincided with a strong positive reaction. The Dec 23, 2025 move to a 24‑month shelf life also aligned with a gain. Today’s 2025 recap and 2026 outlook fit this sequence of operational progress updates.

Market Pulse Summary

This announcement consolidates Bone Biologics’ 2025 milestones, including achieving a 24‑month shelf life for rhNELL-1, strengthening its capital position with a $5 million offering, and maintaining Nasdaq compliance, while outlining NB1 clinical progress goals for 2026. In recent months, similar updates on shelf-life improvements and NB1 development coincided with constructive price reactions. Investors may focus on execution of first-in-human trial enrollment, continued IP expansion, and capital management as key markers of future progress.

Key Terms

rhNELL-1 medical

"extension of the validated shelf life of our rhNELL-1 protein"

rhNELL-1 is a lab-made form of a human protein that encourages bone growth and repair; think of it as a biological fertilizer that helps bone cells multiply and knit broken or missing bone together. For investors, it matters because therapies based on this protein aim to treat conditions like bone fractures, spinal fusion needs or severe bone loss, so clinical trial results, safety data and regulatory approval prospects directly affect a company’s future revenue and risk profile.

registered public offering financial

"completed a registered public offering for total gross proceeds of $5 million"

A registered public offering is when a company files required documents with regulators to sell new shares or bonds to the general public, providing standardized financial and business information for transparency. For investors, it matters because it creates an opportunity to buy newly issued securities while often increasing market liquidity, but it can also dilute existing ownership and affect share price as supply and company funding needs change—think of a bakery baking extra loaves that can satisfy more customers but slightly reduces each owner's slice of the original batch.

first-in-human clinical trial medical

"completion of patient enrollment in its first-in-human clinical trial"

A first-in-human clinical trial is the first time a new drug or medical treatment is given to people rather than tested only in the lab or animals, aimed mainly at checking safety, appropriate dose, and initial side effects. For investors, it marks a major step from concept to real-world testing—like taking a prototype car onto a closed track—and carries high risk but also the potential to unlock significant value if results are favorable.

U.S. patent application regulatory

"filed a U.S. patent application related to its bone regeneration technology"

A U.S. patent application is a formal request filed with the U.S. Patent and Trademark Office asking for legal protection over an invention, describing how it works and why it’s new. For investors, it signals a company is trying to secure exclusive rights that can block competitors or create licensing income—like reserving a valuable spot in a crowded market—and can affect a company’s future revenue potential and risk profile.

Nasdaq’s minimum bid price requirement regulatory

"regained compliance with Nasdaq’s minimum bid price requirement"

A Nasdaq minimum bid price requirement is a listing rule that a stock must trade above a set dollar level (commonly $1) for a sustained period to remain on the exchange; failure to meet the threshold can trigger warnings and possible removal. Investors care because falling below that floor can shrink a stock’s market visibility, reduce trading options and liquidity, and increase the risk that the company’s shares will be delisted, similar to a product being pulled from store shelves when it no longer meets basic sales standards.

AI-generated analysis. Not financial advice.

Key accomplishments include expanded rhNELL-1 shelf life, advanced NB1 development, strengthened balance sheet, and maintained Nasdaq compliance

BURLINGTON, Mass., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Bone Biologics Corporation ("Bone Biologics" or the "Company") (NASDAQ: BBLG, BBLGW), a developer of orthobiologic products for spine fusion markets, today summarized key corporate, scientific, and operational milestones achieved during 2025 and outlined its strategic outlook for 2026.

“We executed with discipline throughout 2025 as we focused on strengthening the foundation required to advance our clinical program,” stated Bone Biologics CEO Jeff Frelick. “During the year, we made meaningful progress across product readiness, intellectual property, and capital structure, including extending the validated shelf life of our rhNELL-1 protein and completing financings that position us to continue advancing NB1. As we enter 2026, our goal remains the thoughtful progression of our clinical development efforts while maintaining capital discipline and creating long-term value for all our stakeholders.”

2025 Highlights
The Company focused on executing against its strategic priorities across development, operations, and corporate governance. The milestones below reflect the Company’s efforts to support ongoing program, maintain organizational stability, and position the business for future advancement.

• Extended rhNELL-1 Product Shelf Life — In December 2025, the Company announced the successful extension of the validated shelf life of its lead rhNELL-1 protein product candidate to 24 months, advancing prior 12- and 18-month stability milestones. This improvement supports manufacturing efficiency, supply-chain flexibility, and clinical readiness
• Strengthened Capital Position — Bone Biologics completed a registered public offering for total gross proceeds of $5 million during the second quarter of 2025, providing funding to support ongoing clinical development activities, intellectual property initiatives, and general corporate purposes
• Expanded Intellectual Property Portfolio — The Company filed a U.S. patent application related to its bone regeneration technology based on recombinant human NELL-1, further strengthening its proprietary platform
• Maintained Nasdaq Listing Compliance — In June 2025, Bone Biologics regained compliance with Nasdaq’s minimum bid price requirement, reinforcing its continued access to the public capital markets
• Increased Investor Engagement — Management participated in the H.C. Wainwright 27th Annual Global Investment Conference and issued a detailed stockholder letter outlining progress across the Company’s clinical and operational initiatives

Outlook for 2026
As the Company enters 2026, it plans to remain focused on advancing its clinical-stage program and strengthening its operational foundation:

• Clinical Development Progression — Continuing advancement of NB1, the Company’s rhNELL-1-based bone graft product candidate, including the expected completion of patient enrollment in its first-in-human clinical trial and potential interim updates, as appropriate
• Operational and Manufacturing Execution — Ongoing efforts to support regulatory readiness and future commercialization planning
• Intellectual Property Strategy — Continuing pursuit of relevant patent protections to enhance long-term platform value
• Financial Discipline and Strategic Focus — Maintaining prudent capital management while supporting scientific progress and shareholder engagement

About Bone Biologics
Bone Biologics was founded to pursue regenerative medicine for bone. The Company is undertaking work with select strategic partners that builds on the preclinical research of the NELL-1 protein. Bone Biologics is focusing development efforts for its bone graft substitute product on bone regeneration in spinal fusion procedures, while additionally having rights to trauma and osteoporosis applications. For more information, please visit www.bonebiologics.com.

Forward-Looking Statements
Certain statements contained in this press release, including, without limitation, statements regarding the Company’s strategic outlook and expected achievements for the year 2026, timing, implementation, and success of the Company's pilot clinical study, the Company’s development of rhNELL-1 and achievement of operational milestones, the ability of the Company’s lead product candidate NB1 to provide rapid, specific and guided control over bone regeneration and show fusion success in humans, the ability of NB1 to compete in global markets, the Company’s performance as a public company, as well as statements containing the words "anticipate," "may," "believe," “continue,” “goal,” “plan,” "expect," “outlook,” and words of similar import, constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve both known and unknown risks and uncertainties. The Company’s actual results may differ materially from those anticipated in its forward-looking statements as a result of a number of factors, including, but not limited to, market and other conditions and risks generally associated with an undercapitalized developing company, as well as the risks contained under "Risk Factors" and "Management’s Discussion and Analysis of Financial Condition and Results of Operations" in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024 and the Company’s other filings with the Securities and Exchange Commission. Except as required by applicable law, we undertake no obligation to revise or update any forward-looking statements to reflect any event or circumstance that may arise after the date hereof.

Contacts

CORE IR
(212) 655-0924
investors@bonebiologics.com

FAQ

What did Bone Biologics (BBLG) announce about rhNELL-1 shelf life on January 8, 2026?

The company extended the validated shelf life of its rhNELL-1 protein product candidate to 24 months in December 2025.

How much capital did Bone Biologics (BBLG) raise in 2025 and when?

Bone Biologics completed a registered public offering that generated $5.0 million in gross proceeds during Q2 2025.

What is Bone Biologics' (BBLG) 2026 clinical development plan for NB1?

The company expects to continue advancing NB1, including the expected completion of patient enrollment in its first-in-human clinical trial and potential interim updates as appropriate.

When did Bone Biologics (BBLG) regain Nasdaq compliance?

Bone Biologics regained compliance with Nasdaq's minimum bid price requirement in June 2025.

Did Bone Biologics (BBLG) take steps to protect its technology in 2025?

Yes, the company filed a U.S. patent application related to its recombinant human NELL-1 bone regeneration technology in 2025.